Jazz Pharmaceuticals Plc PT Raised to $195.00 at Stifel Nicolaus (JAZZ)
Equities researchers at Stifel Nicolaus raised their price target on shares of Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) from $145.00 to $195.00 in a research report issued on Wednesday, StockRatingsNetwork reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ target price suggests a potential upside of 11.44% from the company’s current price.
Several other analysts have also recently commented on the stock. Analysts at Cantor Fitzgerald downgraded shares of Jazz Pharmaceuticals Plc from a “buy” rating to a “hold” rating in a research note on Wednesday. They now have a $182.00 price target on the stock, up previously from $170.00. Separately, analysts at Piper Jaffray raised their price target on shares of Jazz Pharmaceuticals Plc from $159.00 to $201.00 in a research note on Wednesday. They now have an “overweight” rating on the stock. Finally, analysts at Guggenheim raised their price target on shares of Jazz Pharmaceuticals Plc from $140.00 to $210.00 in a research note on Wednesday. They now have a “buy” rating on the stock. Four analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $154.00.
Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) traded down 5.70% on Wednesday, hitting $165.01. 2,150,697 shares of the company’s stock traded hands. Jazz Pharmaceuticals Plc has a one year low of $50.76 and a one year high of $176.60. The stock’s 50-day moving average is $153.2 and its 200-day moving average is $111.9. The company has a market cap of $9.536 billion and a P/E ratio of 29.74.
Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, February 25th. The company reported $1.72 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.78 by $0.06. The company had revenue of $235.80 million for the quarter, compared to the consensus estimate of $238.12 million. On average, analysts predict that Jazz Pharmaceuticals Plc will post $6.37 earnings per share for the current fiscal year.
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.